TSE:BCT BriaCell Therapeutics (BCT) Stock Price, News & Analysis C$4.55 -0.09 (-1.94%) As of 07/3/2026 02:43 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesBuy This Stock About BriaCell Therapeutics Stock (TSE:BCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's RangeC$4.45▼C$5.0050-Day RangeC$3.80▼C$5.7352-Week RangeC$3.68▼C$40.60Volume1,800 shsAverage Volume20,567 shsMarket CapitalizationC$39.59 millionP/E RatioN/ADividend Yield13.70%Price TargetN/AConsensus RatingN/A Company Overview BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients' lives. Immunotherapies have become the forefront of the fight against cancer because they use the body's immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence. Read More Receive BCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCT Stock News HeadlinesBriaCell Therapeutics (TSE:BCT) Trading 1.6% Higher - What's Next?June 30, 2026 | americanbankingnews.comBriaCell Therapeutics Corp.: BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast CancerMay 6, 2026 | finanznachrichten.deSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.July 5 at 1:00 AM | Weiss Ratings (Ad)BriaCell: Advancing Toward Approval with Late-Stage Breast Cancer ImmunotherapyApril 17, 2026 | theglobeandmail.comBriaCell Shareholders Overwhelmingly Back Board and Auditors at Annual MeetingMarch 20, 2026 | theglobeandmail.comBriaCell to Spotlight Phase 3 Bria-IMT Data and Next-Gen Bria-OTS+ Platform at 2026 AACRMarch 20, 2026 | theglobeandmail.comBriaCell Therapeutics stock plummets after $30 million offeringJanuary 14, 2026 | in.investing.comBriaCell to Present Key Clinical Data at SABCS 2025November 18, 2025 | msn.comSee More Headlines BCT Stock Analysis - Frequently Asked Questions How have BCT shares performed this year? BriaCell Therapeutics' stock was trading at C$9.80 on January 1st, 2026. Since then, BCT stock has decreased by 53.6% and is now trading at C$4.55. When did BriaCell Therapeutics' stock split? BriaCell Therapeutics's stock reverse split on Sunday, August 24th 2025.The 1-10 reverse split was announced on Sunday, August 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of BriaCell Therapeutics? Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:BCT CIKN/A Webwww.briacell.com Phone604-921-1810FaxN/AEmployees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.37 million Net MarginsN/A Pretax MarginN/A Return on Equity-147.92% Return on Assets-122.71% Debt Debt-to-Equity RatioN/A Current Ratio7.07 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueC$3.23 per share Price / Book1.41Miscellaneous Outstanding Shares8,700,000Free FloatN/AMarket CapC$39.59 million OptionableNot Optionable Beta1.98 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (TSE:BCT) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
